Bullous Pemphigoid Treatment Market Is Driven By Increasing Incidence Rates Of Bullous Pemphigoid

By Author: colin
Total Articles: 197
Comment this article

Bullous pemphigoid is an autoimmune disease that causes painful blisters on the skin and mucous membranes characterized by the formation of large, fluid-filled blisters (bullae). The disease is caused by the production of antibodies against components of the dermal-epidermal junction. Bullous pemphigoid most commonly affects older adults and is typically treated with topical or oral corticosteroids.
The Bullous Pemphigoid Market is estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a 10% CAGR over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, Roche. Key players in the market are focusing on developing novel treatment options such as monoclonal antibody therapies to expand their product portfolio and market share.
There is a growing demand for effective treatment options for bullous pemphigoid due to increasing incidence rates worldwide especially among elderly population. The increasing healthcare expenditure in emerging markets is also supporting the growth of bullous pemphigoid ...
... treatment market.
Globally, the bullous pemphigoid treatment market is expanding significantly particularly in Asia Pacific and Latin America due to growing geriatric population, improving access to healthcare facilities and increasing per capita healthcare expenditure in these regions.
Market Drivers
The major driver for bullous pemphigoid market is the increasing incidence and prevalence rates of the disease globally. According to epidemiological studies, the incidence of bullous pemphigoid ranges between 1.2-42 cases per million and is increasingly common in adults over 60 years of age. Further, improved diagnosis and growing awareness about the disease amongst physicians and patients is significantly supporting the growth of this market.
The ongoing war between Russia and Ukraine is significantly impacting the growth of the bullous pemphigoid market. The sanctions imposed on Russia due to the invasion have created major supply chain disruptions for raw materials used in bullous pemphigoid drugs. Most of the ingredients utilized in corticosteroids and immunosuppressant medications prescribed for bullous pemphigoid are majorly sourced from Russia and Ukraine. The halted export activities from these countries have led to a spike in commodity prices globally. Pharmaceutical companies are facing severe shortages and inflated costs of API, which is negatively affecting their production output and profit margins. To overcome this challenge, manufacturers will need to establish alternative long-term supply sources from other regions like Asia, the Middle East and South America. They also must appropriately stock sufficient quantities of critical ingredients to avoid future disruptions.
Europe has traditionally dominated the Bullous Pemphigoid Market in terms of value, holding over 30% share. This is because European countries have a predominantly aging population that is more susceptible to autoimmune blistering conditions. Countries like Germany, France, UK and Italy have widespread medical reimbursement programs that incentivize early diagnosis and treatment of bullous pemphigoid. However, the ongoing war has dampened economic activities and healthcare investments in major markets of Eastern Europe. To compensate for losses from the region, companies should focus on expanding their geographic footprint in underpenetrated Western European nations through new product launches and aggressive marketing initiatives targeting dermatologists.
The Asia Pacific region has emerged as the fastest growing market for bullous pemphigoid globally. Factors such as increasing life expectancy, growing medical tourism industry and rising healthcare expenditures are fueling the demand. China and India with their huge patient pools represent key high potential markets. Favorable regulations and lower manufacturing costs have also attracted many global drug makers to set up production facilities in these Asian countries. To sustain the momentum, companies must raise local population's disease awareness, improve diagnostic rates and prioritize the region in new clinical trial programs and brand promotions.
Europe relies heavily on imported ingredients from sanctioned countries like Russia and Ukraine for bullous pemphigoid drugs. Alternative longterm supply sources and sufficient stockpiles need to be established to overcome shortages and price increases resulting from geopolitical tensions. While Europe dominates the market currently, Asia Pacific region is expanding rapidly owing to various socioeconomic factors. Focusing on marketing initiatives and operations in underpenetrated Western European markets and high growth Asia Pacific nations will be imperative for companies to offset losses from sanctions impacted Eastern European regions.
Get more insights on this topic:https://www.zupyak.com/p/4293490/t/the-bullous-pemphigoid-market-is-expected-to-witness-high-growth-owing-to-increasing-awareness-regarding-symptoms-and-treatment-options

Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Bullous Pemphigoid Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors
FAQ’s
Q.1 What are the main factors influencing the Bullous Pemphigoid Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it